{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:22:37Z","timestamp":1787869357800,"version":"build-2784847793"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["912192"],"award-info":[{"award-number":["912192"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019802","name":"BioTechMed-Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["864690"],"award-info":[{"award-number":["864690"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["870454"],"award-info":[{"award-number":["870454"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clnu.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T15:57:24Z","timestamp":1764431844000},"page":"106522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study"],"prefix":"10.1016","volume":"56","author":[{"given":"Daniel","family":"Habich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Feldbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavra","family":"Rebol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Nepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Madl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00f6rg","family":"Habisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Baumann-Durchschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"F\u00fcrst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Plank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Spindelb\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf E.","family":"Stauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Tatscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot","family":"Zollner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-8271","authenticated-orcid":false,"given":"Vanessa","family":"Stadlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2025.11.007_bib1","series-title":"HEPAHEALTH project report","author":"Pimpin","year":"2018"},{"key":"10.1016\/j.clnu.2025.11.007_bib2","article-title":"Trends and the course of liver cirrhosis and its complications in Germany: nationwide population-based study (2005 to 2018)","volume":"12","author":"Gu","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"Suppl 1","key":"10.1016\/j.clnu.2025.11.007_bib3","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jhep.2020.12.005","article-title":"Transition to decompensation and acute-on-chronic liver failure: role of predisposing factors and precipitating events","volume":"75","author":"Gustot","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome in liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clnu.2025.11.007_bib5","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/liv.14382","article-title":"Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis","volume":"40","author":"Stadlbauer","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.clnu.2025.11.007_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut-liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.clnu.2025.11.007_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48352-5","article-title":"Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis","volume":"9","author":"Horvath","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2025.11.007_bib9","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/apt.13788","article-title":"Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis","volume":"44","author":"Horvath","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2025.11.007_bib10","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3390\/nu12061874","article-title":"Changes in the intestinal microbiome during a multispecies probiotic intervention in compensated cirrhosis","volume":"12","author":"Horvath","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2025.11.007_bib11","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41598-020-59550-x","article-title":"The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: a pilot study","volume":"10","author":"Horvath","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2025.11.007_bib12","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1007\/s00394-019-02135-w","article-title":"Effects of a multispecies synbiotic on glucose metabolism, lipid marker, gut microbiome composition, gut permeability, and quality of life in diabesity: a randomized, double-blind, placebo-controlled pilot study","volume":"59","author":"Horvath","year":"2020","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.clnu.2025.11.007_bib13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1665-2681(19)31989-1","article-title":"Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study","volume":"5","author":"Poo","year":"2006","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the study of the liver. EASL clinical practice guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40265-018-1023-2","article-title":"Pharmacokinetic and pharmacodynamic properties of L-Ornithine L-Aspartate (LOLA) in hepatic encephalopathy","volume":"79","author":"Kircheis","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clnu.2025.11.007_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/nu14040748","article-title":"Oral intake of L-Ornithine-L-Aspartate is associated with distinct microbiome and metabolome changes in cirrhosis","volume":"14","author":"Horvath","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2025.11.007_bib17","series-title":"SF-36 Fragebogen zum Gesundheitszustand Handanweisung. Goettingen","author":"Bullinger","year":"1998"},{"key":"10.1016\/j.clnu.2025.11.007_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1365-2265.2011.04120.x","article-title":"Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis","volume":"75","author":"Han","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.clnu.2025.11.007_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1193110","article-title":"Irisin, in women and men: blood pressure, heart rate, obesity and insulin resistance","volume":"14","author":"Almeida Gonz\u00e1lez","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2025.11.007_bib20","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4254\/wjh.v16.i5.832","article-title":"Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease","volume":"16","author":"Lange","year":"2024","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib21","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3698","article-title":"Genomic and functional analysis of Romboutsia ilealis CRIBT reveals adaptation to the small intestine","volume":"5","author":"Gerritsen","year":"2017","journal-title":"PeerJ"},{"key":"10.1016\/j.clnu.2025.11.007_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1438897","article-title":"Akkermansia muciniphila is associated with normal muscle mass and Eggerthella is related with sarcopenia in cirrhosis","volume":"11","author":"Efremova","year":"2024","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnu.2025.11.007_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/apt.17256","article-title":"A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis","volume":"57","author":"Liwinski","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2025.11.007_bib24","article-title":"Selenium-enriched Lactobacillus acidophilus ameliorates dextran sulfate sodium-induced chronic colitis in mice by regulating inflammatory cytokines and intestinal microbiota","volume":"8","author":"Wu","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.clnu.2025.11.007_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032335","article-title":"Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: a systematic review and meta-analysis","volume":"101","author":"Huang","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.clnu.2025.11.007_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.gastro.2020.08.054","article-title":"Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis","volume":"160","author":"Sol\u00e9","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clnu.2025.11.007_bib27","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i1.100377","article-title":"Gut microbiome composition in patients with liver cirrhosis with and without hepatic encephalopathy: a systematic review and meta-analysis","volume":"17","author":"Xu","year":"2025","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib28","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98019","article-title":"Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis","volume":"3","author":"Bajaj","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.clnu.2025.11.007_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41467-017-00796-x","article-title":"Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal enterococcus","volume":"8","author":"Llorente","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.clnu.2025.11.007_bib30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fmicb.2018.01791","article-title":"The genus enterococcus: between probiotic potential and safety Concerns-An update","volume":"9","author":"Hanchi","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.clnu.2025.11.007_bib31","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3390\/microorganisms9091900","article-title":"The many faces of enterococcus spp.-Commensal, probiotic and opportunistic pathogen","volume":"9","author":"Krawczyk","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.clnu.2025.11.007_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/hep.510300311","article-title":"L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure","volume":"30","author":"Rose","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2025.11.007_bib33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40265-018-1020-5","article-title":"L-Ornithine L-Aspartate (LOLA) as a novel approach for therapy of non-alcoholic fatty liver disease","volume":"79","author":"Canbay","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clnu.2025.11.007_bib34","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/jcsm.13342","article-title":"Altered gut microbiome, bile acid composition and metabolome in sarcopenia in liver cirrhosis","volume":"14","author":"Aliwa","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.clnu.2025.11.007_bib35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jhep.2020.01.026","article-title":"HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure","volume":"73","author":"Trieb","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bbalip.2016.04.013","article-title":"Liver disease alters high-density lipoprotein composition, metabolism and function","volume":"1861","author":"Trieb","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clnu.2025.11.007_bib37","unstructured":"KEGG COMPOUND: C00041 [Internet]. n.d. [cited 2025 Jun 27]. Available from: https:\/\/www.kegg.jp\/entry\/C00041."},{"key":"10.1016\/j.clnu.2025.11.007_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.14474","article-title":"Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation","volume":"47","author":"Rainer","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2025.11.007_bib39","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/nu12092728","article-title":"Secondary sclerosing cholangitis in critically ill patients alters the gut-liver axis: a case control study","volume":"12","author":"Blesl","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2025.11.007_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12985-019-1219-4","article-title":"Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"10.1016\/j.clnu.2025.11.007_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106562","article-title":"Liver lipopolysaccharide binding protein prevents hepatic inflammation in physiological and pathological non-obesogenic conditions","volume":"187","author":"Milbank","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clnu.2025.11.007_bib42","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/liv.13264","article-title":"High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis","volume":"37","author":"Agiasotelli","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clnu.2025.11.007_bib43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.21737","article-title":"Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome","volume":"46","author":"Mookerjee","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2025.11.007_bib44","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2010.11.034","article-title":"Evidence of neutrophil functional defect despite inflammation in stable cirrhosis","volume":"55","author":"Tritto","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib45","doi-asserted-by":"crossref","first-page":"G15","DOI":"10.1152\/ajpgi.90512.2008","article-title":"Role of toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis","volume":"296","author":"Stadlbauer","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clnu.2025.11.007_bib46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5114\/ceh.2018.80124","article-title":"Health-related quality of life in liver cirrhosis patients using SF-36 and CLDQ questionnaires","volume":"4","author":"Janani","year":"2018","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MEG.0b013e3283319975","article-title":"Quality of life in cirrhosis is related to potentially treatable factors","volume":"22","author":"Les","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib48","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.3748\/wjg.v13.i21.3003","article-title":"Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy","volume":"13","author":"Bao","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clnu.2025.11.007_bib49","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000159","article-title":"Psychological burden of hepatic encephalopathy on patients and caregivers","volume":"11","author":"Fabrellas","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clnu.2025.11.007_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12955-022-01923-z","article-title":"Continued alcohol consumption and hepatic encephalopathy determine quality of life and psychosocial burden of caregivers in patients with liver cirrhosis","volume":"20","author":"Nagel","year":"2022","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.clnu.2025.11.007_bib51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11011-012-9325-7","article-title":"A patients' and caregivers' perspective on hepatic encephalopathy","volume":"27","author":"Montagnese","year":"2012","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.clnu.2025.11.007_bib52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11586700-000000000-00000","article-title":"Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study","volume":"31","author":"Ong","year":"2011","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clnu.2025.11.007_bib53","first-page":"A117","article-title":"PWE-091 L-ornithine L-aspartate in minimal hepatic encephalopathy: possible effects on the brain-muscle axis?","volume":"67","author":"Pasha","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.clnu.2025.11.007_bib54","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2025.11.007_bib55","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","article-title":"Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study","volume":"28","author":"Stauch","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-018-1024-1","article-title":"L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses","volume":"79","author":"Butterworth","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.clnu.2025.11.007_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62293-8","article-title":"Intravenous versus oral \u201cL-ornithine-L-aspartate\u201d in overt hepatic encephalopathy: a randomized comparative study","volume":"14","author":"Jhajharia","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2025.11.007_bib58","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/ndt\/gfr354","article-title":"Pitfalls in assessing renal function in patients with cirrhosis--potential inequity for access to treatment of hepatorenal failure and liver transplantation","volume":"26","author":"Davenport","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clnu.2025.11.007_bib59","article-title":"L-Ornithine L-Aspartate for the treatment of sarcopenia in chronic liver disease: the taming of a vicious cycle","volume":"2019","author":"Butterworth","year":"2019","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2025.11.007_bib60","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.29107","article-title":"Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis","volume":"65","author":"Kumar","year":"2017","journal-title":"Hepatology"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:57:38Z","timestamp":1777532258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561425003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":60,"alternative-id":["S0261561425003048"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2025.11.007","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106522"}}